David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the potential of the triplet therapy pivekimab sunirine combined with venetoclax and azacitidine for newly diagnosed CD123-positive acute myeloid leukemia (AML). Favorable response rates in a Phase IB/II trial suggest the next step is a Phase III trial comparing this triplet to a doublet, with overall survival (OS) as the primary endpoint. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть